Ductal Carcinoma in Situ Clinical Trial
Official title:
A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Post-menopausal women with biopsy-proven DCIS will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhibitor alone for about 12 weeks prior to surgery at 12 weeks. The second cohort will receive neoadjuvant therapy with an aromatase inhibitor and MUC1 vaccination (MUC1 peptide + Hiltonol®) pre-operatively at baseline, and weeks 2 and 10, followed by surgery at about 12 weeks. Patients in the vaccine cohort will be offered an optional boost vaccine 6 months after surgery.
DCIS is frequently detected by screening mammography, and may develop into invasive disease. However, not all DCIS will progress to invasive breast cancer, and some patients are overtreated. Vaccines for DCIS might facilitate therapeutic de-escalation, and allow less aggressive therapy. The TAA MUC1 is expressed in DCIS, and vaccines specific for MUC1 are safe and decrease the rate of recurrence of high-risk premalignant lesions in colon cancer. This clinical trial is designed to evaluate mechanisms of immune activation and suppression in patients with DCIS, both within the peripheral blood and within the DCIS lesion, and will provide data to guide the development of larger trials to evaluate the impact of a MUC1 vaccine to prevent disease recurrence. Ultimately, vaccine success in intercepting the development of breast cancer will provide critical data for the application of these strategies in breast cancer prevention in high-risk individuals. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02889458 -
Hong Kong Breast Cancer Study
|
||
| Completed |
NCT00757302 -
Intraoperative Gamma Camera for Breast Cancer Surgery
|
Phase 3 | |
| Recruiting |
NCT03216421 -
Intraoperative Radiation Therapy (IORT) in DCIS
|
N/A | |
| Completed |
NCT03775213 -
Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)
|
N/A | |
| Active, not recruiting |
NCT00605982 -
Breast MRI as a Preoperative Tool for DCIS
|
N/A | |
| Enrolling by invitation |
NCT04365114 -
Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening
|
||
| Completed |
NCT04248179 -
The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.
|
Phase 4 | |
| Withdrawn |
NCT05032079 -
Subzero and Scorpion Trial
|
N/A | |
| Recruiting |
NCT05218044 -
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
|
N/A | |
| Active, not recruiting |
NCT01644669 -
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
|
N/A | |
| Recruiting |
NCT06133647 -
Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System
|
||
| Completed |
NCT01815476 -
The Prone Breast Radiation Therapy Trial
|
N/A | |
| Not yet recruiting |
NCT06033092 -
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
|
Phase 2 | |
| Terminated |
NCT02137252 -
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
|
Phase 2 | |
| Terminated |
NCT01060345 -
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ
|
Phase 2 | |
| Recruiting |
NCT00669747 -
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
|
Phase 2 | |
| Completed |
NCT00742222 -
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
|
Phase 4 | |
| Active, not recruiting |
NCT02909426 -
The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness
|
||
| Recruiting |
NCT02928978 -
Ruxolitinib for Premalignant Breast Disease
|
Phase 2 | |
| Completed |
NCT03375892 -
The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure
|
N/A |